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Background: Each year in China, 30,000 babies are born with congenital hearing impairment. However, the
molecular etiology of hearing impairment in the Yunnan Province population where more than 52 minorities live
has not been thoroughly investigated. To provide appropriate genetic testing and counseling to these families, we
investigated the molecular etiology of nonsyndromic deafness in this population.
Methods: Unrelated students with hearing loss (n = 235) who attended Kunming Huaxia secondary specialized
school in Yunnan enrolled in this study. Three prominent deafness-related genes, GJB2, SLC26A4 and mtDNA 12S
rRNA, were analyzed. High-resolution temporal bone computed tomography (CT) scan examinations were performed
in 100 cases, including 16 cases with SLC26A4 gene variants, and 37 minorities and 47 Han cases without any SLC26A4
gene mutation.
Results: The GJB2 mutation was detected in 16.67% (7/42) of minority patients and 17.62% (34/193) of Chinese Han
patients (P > 0.05). 235delC was the hotspot mutation in nonsyndromic hearing loss (NSHL) patients, whereas 35delG
was not found. The 431_450del19 mutation was detected for the first time in Han NSHL patients, which resulted in a
premature stop codon and changed the protein. The SLC26A4 mutation was found in 9.52% (4/42) of minority patients
and 9.84% (19/193) of Han Chinese patients (P > 0.05). The frequencies of mtDNA 12S rRNA mutation in minority and
Han Chinese patients were 11.90% (5/42) and 7.77% (15/193; P > 0.05), respectively. Sixteen (16/23, 69.57%) patients
with SLC26A4 mutations received temporal bone CT scan, and 14 patients were diagnosed with enlarged vestibular
aqueducts (EVAs); the other 2 patients had normal inner ear development. The ratio of EVA in the minorities was
14.63% (6/41).
Conclusions: In this study, a total of 35.74% deaf patients showed evidence of genetic involvement, based on either
genetic screening or family history; 17.45%, 9.79%, and 8.51% of the patients were determined to have inherited
hearing impairment caused by GJB2, SLC26A4, and mtDNA 1555A > G mutations. There was no significant difference in
deafness associated gene mutational spectrum and frequency between the Yunnan minority and Han patients.
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Hearing impairment is the most common neurosensory
disorder in humans, with an incidence of 1 in 300 to 1
in 1,000 children [1-3] and approximately half of all
cases are caused by genetic defects. GJB2, SLC26A4 and
mitochondrial DNA (mtDNA) 12S rRNA are thought to
be the most common causes of nonsyndromic autosomal
recessive deafness in Asian people. China is a large coun-
try with 1.3 billion people of 56 ethnicities. For effective
genetic testing and accurate counseling, comprehensive
genetic analysis in deaf patients in most Chinese regions
had been performed. However, little is known of the
Yunnan Province, located southeast of mainland China,
where 52 nationalities—including Han and 51 minorities—
live together. Yunnan Province, which comprises more than
52 ethnic groups, is an important cradle of civilization.
Among the 52 Chinese ethnicities, the 16 native to Yunnan
are: Yi, Bai, Hani, Dai, Lisu, Lahu, Wa, Naxi, Jingpo, Brown,
Prattm, Achang, Nu, Jino, Deang and Dulong. Data released
by the Yunnan province Disabled Persons’ Federation
showed that 7.47% (477/6,383) of handicapped out-of-
school children suffered from hearing impairment.
Worldwide, the most common cause of nonsyndromic
autosomal recessive hearing loss is a mutation in con-
nexin 26, a gap-junction protein encoded by the GJB2
gene [4-11]. Defects in SLC26A4, which encodes the
anion (chloride/iodide, chloride/bicarbonate) transporter
Pendrin, can cause nonsyndromic DFNB4 deafness with
enlargement of the vestibular aqueduct (EVA) and Pendred
syndrome [12,13]. A SLC26A4 mutation is the second
most common cause of deafness in China [4]. Although
the majority of cases of hereditary hearing loss are caused
by nuclear gene defects, it has become clear that mutations
in mtDNA can also cause nonsyndromic hearing loss. The
best-studied mutations related to aminoglycoside suscepti-
bility are A1555G and C1494T in the mtDNA 12S rRNA
gene [14-16]. Nonsyndromic inherited hearing impairment
caused by mutations in GJB2, SLC26A4, or mtDNA 12S
rRNA typically account for 33.8% of the cases of deafness
in areas of China [17].
Connexin 26, a gap junction protein encoded by the GJB2
gene, is the most common molecular defect in nonsyndromic
autosomal recessive deafness in China [4-11]. The GJB2 gene
mutational site exhibits racial differences: the high-incidence
mutational site is 30_35delG in Caucasians, 167delT in Jews,
and 233_235delC in Japanese. The molecular epidemiological
investigation of deafness in China shows that GJB2 235delC
has a high prevalence in Chinese deaf populations. Among re-
cessive mutations, 35delG is the most frequent in Caucasians,
167delT in Ashkenazi Jews, 235delC in East Asians, and
R143W in Africans, suggesting the existence of founder
effects in different ethnic groups [7,14-16,18-26].
In the present study, we comprehensively analyzed three
prominent deafness-related genes (i.e., GJB2, SLC26A4,mtDNA 12S rRNA) in 235 patients, including 45 minority
patients from unrelated families in the Yunnan province
who experienced early onset, nonsyndromic hearing im-
pairment, to investigate the molecular etiology of heredi-
tary hearing loss in this region. Detailed genotype and
phenotype analyses were performed to provide effective
risk assessment and genetic counseling for hearing loss
patients and their families in this area.
Materials and Methods
Patients and DNA samples
Unrelated hearing loss patients (n = 235) from Huaxia
secondary special education school in Yunnan province
were enrolled in this study. This cohort of patients con-
sisted of 133 males and 102 females from 17 to 23 years
old, with an average age of 17.26 ± 2.12 years. Huaxia
school is the only secondary special education school
for the disabled in Yunnan, whose students come from
all over the province. The ethnic minority composition in
Huaxia school (30.2%) is consistent with that of the prov-
ince’s. Ethnically, the patients included 193 Han (82.1%),
13 Bai (5.5%), 5 Dai (2.1%), 7 Yi (3.0%), 2 Hani (0.9%), 3
Hui (1.3%), 1 Jingpo (0.4%), 2 Lahu (0.9%), 2 Lisu (0.9%), 5
Nazi (2.1%), 1 Wa (0.4%), and 1 Yao (0.4%) Chinese.
The study protocol was performed with the approval
of the ethnicity committee of the Chinese PLA General
Hospital. Informed consent was obtained from all sub-
jects prior to blood sampling. Parents were interviewed
with regard to age of onset, family history, health of the
mother during pregnancy and the clinical history of the
patient, including infection, possible head or brain in-
jury, and the use of aminoglycoside antibiotics. All sub-
jects had moderate to profound bilateral sensorineural
hearing impairment on audiograms. Careful medical ex-
aminations resulted in two patients being diagnosed with
Waardenburg syndrome. DNA was extracted from the
peripheral blood leukocytes of 235 patients with nonsyn-
dromic hearing loss and 200 region- and race-matched
controls with normal hearing using a commercially avail-
able DNA extraction kit (Watson Biotechnologies Inc,
Shanghai, China).
Mutational analysis
The coding exons plus approximately 50–100 bp of the
flanking intron regions of GJB2, mtDNA 12S rRNA and
SLC26A4 were amplified by polymerase chain reaction
(PCR), then sequenced using the Big Dye sequencing
protocol in all patients. The sequence results were analyzed
using an ABI 3100 DNA sequencing machine (Applied
Biosystems, Foster City, CA) and ABI 3100 Analysis
Software v.3.7 NT, according to the manufacturer’s proto-
col. Patients with monoallelic GJB2 coding region muta-
tions were further tested for GJB2 IVS1 + 1G >A mutation
or defects in GJB2 exon 1 and its basal promoter.
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ally sequenced starting from the frequently mutated
exons 7, 8, 10 and 19. Patients with a single mutation on
the above four exons were screened for the other exons
in SLC26A4.
Two hundred controls with normal hearing were se-
quenced to determine the presence of mutations in the
GJB2 and mtDNA 12S rRNA polymorphisms. In addition,
all controls were screened for SLC26A4 mutations by de-
naturing high-pressure liquid chromatography (DHPLC)
followed by sequencing.
CT scan and thyroid examination
A total of 100 patients, including 16 cases with variants
in SLC26A4, 37 minority patients and 47 Han cases
without any mutations or variants in SLC26A4, were ex-
amined using temporal bone CT scans to diagnose EVA.
EVA diagnosis was based on findings of a diameter of
>1.5 mm at the midpoint between the common crus and
the external aperture [27] or other inner ear malforma-
tions to evaluate Pendred syndrome. Thyroid ultrasound
scans and thyroid hormone level determination was per-
formed in patients with SLC26A4 mutations or variants.
These procedures were performed at the Frist Hospital
of Yunnan province, China. As perchlorate discharge
testing is not a general clinical practice in China, it was
not used in this study.
Statistical method
The statistical analysis was performed using SPSS 15.0
software (statistica package for the Social Sciences). TheTable 1 Genotypes of patients with mutations in the GJB2 ge
Allele1 Allele2
Nucleotide change Consequence or
amino change
Category Nucleo
c.235delC Frameshift Pathogenic c.235de
c.139G > T Glu at 47 into Stop Pathogenic c.139G >
c.176del16 Frameshift Pathogenic c.176de
c.299del AT Frameshift Pathogenic c.299de
c.512insAACG Frameshift Pathogenic c.512ins
c.235delC Frameshift Pathogenic c.299de
c.176del16 Frameshift Pathogenic c.235de
c.235delC Frameshift Pathogenic c.512ins
c.35insG Frameshift Pathogenic c.512ins
c.139G > T Glu at 47 into Stop Pathogenic c.299de
c.9G > A Pathogenic c.235de
c.11G > A Pathogenic c.235de
c.235delC Frameshift Pathogenic
c.512insAACG Frameshift Pathogenic
c.431-450del19 Novelintergroup difference in frequency was compared using
the two-tailed chi-square test. A P-value less than 0.05
was considered statistically significant.
Results
GJB2
Our sequence analysis of the GJB2 gene indicated that
34 patients carried two confirmed pathogenic mutations,
including 25 homozygotes and 9 compound heterozy-
gotes. Seven patients carried one heterozygous patho-
genic mutation without an identified second mutant
allele (Table 1). Thus, 17.45% (41/235) of the patients
had molecular defects in GJB2, which is similar to
the ratio of typical areas in China (18.31%; χ2 = 0.0651,
P > 0.05). Thus, GJB2 mutant alleles accounted for 16.0%
(75/470) of the total alleles in 235 NSHI patients. Of those
patients, 14.45% (34/235) had confirmed molecular eti-
ology, and 2.98% (7/235) carried only one pathogenic mu-
tation. The most common mutant allele was c.235delC,
followed by c.299_300delAT, c.512insAACG, c.139G > T
and c.176del16, which accounted for 11.1% (52/470), 1.7%
(8/470), 1.1% (5/470), 0.6% (3/470) and 0.6% (3/470),
respectively.
c.235delC was the hotspot in this patient cohort,
which reportedly is the most prevalent mutation in East
Asian and Southeast Asian populations, but is not com-
mon in European or Oceania populations [28]. Twenty
patients were homozygous for the c.235delC mutation,
seven were compound heterozygous with another patho-
genic mutation, and five were heterozygous for the
c.235delC mutation (Table 1). One novel frameshiftne




lC Frameshift Pathogenic 20
T Glu at 47 into Stop Pathogenic 1
l16 Frameshift Pathogenic 1
lAT Frameshift Pathogenic 2
AACG Frameshift Pathogenic 1
lAT Frameshift Pathogenic 3
lC Frameshift Pathogenic 1
AACG Frameshift Pathogenic 1
AACG Frameshift Pathogenic 1
lAT Frameshift Pathogenic 1
lC Frameshift Pathogenic 1
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75 mutant alleles (including the unclassified missense
variants) were identified in 41 unrelated patients.
c.235delC alone accounted for 69.33% (52/75) of the
total mutant alleles, compared to 71.64% (96/134) in
typical areas of China [17], 69.18% (101/146) in northern
China [29]. The differences were not significant among
ours and other studies of the Chinese population (χ2 =
0.1240, χ2 = 0.0006, P > 0.05).
The GJB2 mutation frequency was 16.67% (7/42) in mi-
nority patients, involving two mutations (i.e., c.235delC
and c.139G > T) whose allele frequencies were 14.29% (12/
84) and 2.38% (2/84), respectively. Of all the 20 homozy-
gous c.235delC patients, three Yi, two Bai, and one Hui
patient were homozygous for c.235delC. One Dai patient
carried homozygous c.139G > T. The GJB2 mutation
frequency in Han Chinese patients was 17.62% (34/
193), involving nine mutations: c. 235delC, c.299de1AT,
c.512insAACG, c.176del16, c.35insG, c.139G > T, c.9G >
A, c.11G > A, c.431_450del19. The allele frequencies were
10.36% (40/386), 2.07% (8/386), 1.30% (5/386), 0.78%
(3/386), 0.26% (1/386), 0.26% (1/386), 0.26% (1/386),
0.26% (1/386) and 0.26% (1/386) in Han Chinese patients,
respectively. The c.235delC allele frequency in the minor-
ity patients was not significantly different from that in the
Han patients (χ2 = 1.0790, P > 0.05).
We analyzed the GJB2 gene in 200 control subjects
with normal hearing and found three types of deleterious
mutations, c.235delC, c.299_300delAT and c.139G > T,
carried by seven subjects in the heterozygous state. This
suggested a GJB2 mutation carrier rate of ~3.5% (7/200)
in the general population. Meanwhile, the carrier rates of
the GJB2 mutation in Korea, Japan, Taiwan, Ashkenazi
Jews and in the Midwestern United States are reported
to be 2%, 2.08%, 2.55%, 4.76%, and 3.01%, respectively
[5,20,21,30-32].
mtDNA 12S rRNA
Eight and a half percent (20/235) of patients carried the
mtDNA 12S rRNA 1555A > G mutation. Among the 20
patients, 7 had a clear history of aminoglycoside use. The
frequency of 1555A >G mutation was 7.77% (15/193) in
Han patients and 11.90% (5/42) in minority patients. The
five minority patients consisted of two Bai, one Naxi, one
Hani and one Hui. None of the 200 control subjects were
found to carry the 1555A >G mutation.
SLC26A4
Sequence analysis of the SLC26A4 gene in these 235 pa-
tients identified nine patients with two confirmed patho-
genic mutations, and five patients carried one confirmed
pathogenic mutation. Six patients were compound het-
erozygous for one pathogenic mutation and one unclas-
sified variant, and three patients carried one unclassifiedvariant (Table 2). Thus, mutations in SLC26A4 were
identified in 9.97% (23/235) of patients with hearing im-
pairment in this study.
A total of seven different pathogenic mutations (IVS7-
2A >G, c.2168A >G, c.84C >A, c.1975G >C, c.754 T > C,
c.1548insG, IVS9 + 1G >A) and six unclassified variants
(intro6-75_76insTGTG, IVS11 + 47 T > C, c.2265C > A,
IVS5 + 27 T > C, IVS7 + 35A >G, IVS7 + 40G >A) were
found (Table 2). The c.1548insG mutation resulted in a
premature stop codon and a truncated protein with only
526 amino acid residues. For those mutations, IVS7-2A >
G, c.2168A >G, c.84C >A, c.1975G >C, c.754 T > C and
IVS9 + 1G >A, were previously reported in patients with
hearing loss [33-38]. For other variants, IVS11 + 47 T > C,
c.2265C > A, IVS5 + 27 T > C, IVS7 + 35A >G, IVS7 +
40G >A and intro6-75-76insTGTG, the NNSPLICE soft-
ware, available at http://www.fruitfly.org/seq_tools/splice.
html was used for analysis. The results indicated that
those variants did not predict gain or loss of a splice site
with this variant, and those variants were considered be-
nign. Thus, SLC26A4 mutant alleles accounted for 82.61%
(38/46) of the total alleles in 235 NSHI patients. For those
patients, 43.48% (10/23) had a confirmed molecular eti-
ology, and 43.48% (10/23) carried only one pathogenic
mutation.
IVS7-2A > G was the hotspot mutation region in this
patient cohort, for which five patients were homozygous,
six were compound heterozygous, and four were hetero-
zygous (Table 2). One of the four patients with the het-
erozygous IVS7-2A > G mutation was also homozygous
for the GJB2 c.235delC mutation. Thus, this patient may
be only an IVS7-2A > G carrier, with defects in GJB2 be-
ing the main cause of hearing loss. The IVS7-2A > G
mutation accounted for 64.63% (53/82, counting only
the definite pathogenic and most likely pathogenic vari-
ants) of all SLC26A4 mutant alleles in this population.
The SCL26A4 mutation frequency was 9.52% (4/42)
in minority patients, involving six mutations: IVS7-2A >
G, c.intron6-75_76insTGTG, c.2168A >G, c.84A >G, c.
IVS11 + 47 T > C and c.1548insG. One Hui carried
IVS7-2A >G/IVS7-2A >G, one Yi carried IVS7-2A >G/
1548insC, one Bai carried IVS7-2A >G/IVS5 + 27 T > C
and one Zhuan carried IVS11 + 47 T > C/1548insC.
The allele frequencies were 2.38% (2/84), 1.19% (1/84),
1.19% (1/84), 1.19% (1/84), 1.19% (1/84) and 1.19% (1/84)
for IVS7-2A >G, c.intron6-75_76insTGTG, c.2168A >G,
c.84A >G, IVS11 + 47 T > C and c.1548insG, respectively.
For the Han Chinese population, SLC26A4 mutation
frequency was 9.84% (19/193), involving 11 mutations:
IVS7-2A > G, c.2168A > G, c.1079 T > C, c.1975G > C,
c.754 T > C, IVS9 + 1G > A, IVS11 + 47 T > C, c.2265C >
A, IVS5 + 27 T > C, IVS7 + 35A > G and IVS7 + 40G >
A. The allele frequencies were 6.64% (19/286) for
IVS7-2A > G, 1.05% (3/286) for c.2168A > G, 0.70% (2/
Table 2 Genotypes of SLC26A4 gene-related hearing impairment in Yunnan
Allele1 Allele2
Nucleotide change Consequence or
amino change




c.IVS7-2A > G aberrant splicing Pathogenic c.IVS7-2A > G aberrant splicing Pathogenic 4 EVA
c.IVS7-2A > G aberrant splicing Pathogenic c.IVS7-2A > G aberrant splicing Pathogenic 1 nl
c.IVS7-2A > G aberrant splicing Pathogenic c.754 T > C S252P Pathogenic 1 ND
c.IVS7-2A > G aberrant splicing Pathogenic c.1548insC FX517,526X Pathogenic 1 EVA
c.2168A > G H723R Pathogenic c.1079 T > C A360V Pathogenic 1 EVA
c.2168A > G H723R Pathogenic c.84C > A S28R Pathogenic 1 nl
c.IVS7-2A > G aberrant splicing Pathogenic c.1975G > C V659L Pathogenic 1 EVA
c.IVS7-2A > G aberrant splicing Pathogenic c.IVS9 + 1G > A aberrant splicing Pathogenic 2 EVA
c.IVS7-2A > G aberrant splicing Pathogenic c.2265C > A T755T Silent variant 1 EVA
c.IVS7-2A > G aberrant splicing Pathogenic c.IVS5 + 27 T > C Variant in intron Unclassified variant 1 EVA
c.1548insC FX517,526X Pathogenic c.IVS11 + 47 T > C Variant in intron Unclassified variant 1 EVA
c.2168A > G H723R Pathogenic 1 EVA
c.IVS7-2A > G aberrant splicing Pathogenic 3 nl
c.IVS7-2A > G aberrant splicing Pathogenic 1 EVA
c.intron6-75_ 76 insTGTG aberrant splicing Unclassified variant 1 nl
c.IVS7 + 35A > G Variant in intron Unclassified variant 1 nl
c.IVS7 + 40G > A Variant in intron Unclassified variant 1 nl
WT WT 2 EVA
nl, normal; EVA, enlarged vestibular aqueduct; IVS7, intravening sequence7(intron 7); IVS9, intravening sequence9(intron 9); IVS5, intravening sequence5(intron 5);
IVS11, intravening sequence11(intron 11); WT, wildtype.
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Temporal bone CT scan
A total of 100 cases, comprised of 16 cases with
SLC26A4 mutations (12 Han Chinese patients and four
minority patients) and 84 control cases without any
SLC26A4 mutations or variants (37 minority cases and
47 Han Chinese patients), were examined by temporal
bone CT scan. Bilateral EVA was detected in 16 patients
(14 patients with SLC26A4 mutation, 2 without SLC26A4
mutation) (Table 2). Four patients carried a homozygous
IVS7-2A >G mutation, five carried a compound heterozy-
gous IVS7-2A >G/1548insC, 2168A >G/84C >A, IVS7-
2A >G/IVS9 + 1G >A and IVS7-2A >G/1975G >C, and
five carried only one pathogenic mutation(IVS7-2A >G,
1548insC and 2168A >G); another two were from the mi-
nority control patients without any SLC26A4 mutations or
variants. Temporal CT scan results were normal in the
remaining patients (Table 2).
Regarding race, six minority patients (one Hui, one
Bai, one Zhuang, and three Yi) presented with EVA. Four
(4/42, 9.52%) of six patients carried a SLC26A4 mutation,
whose genotypes were: IVS7-2A >G/IVS7-2A >G, IVS7-
2A >G/IVS5 + 27 T > C, IVS11 + 47 T > C/1548insC,
2168A >G/84C >A. The EVA ratio in the Chinese deafpopulation was at least 11%, and that in patients of Han
ethnicity reached at least 13%.
Discussion
Many hearing loss-related gene mutations have been de-
scribed to date, most of which are isolated mutations in
some populations. In this study, mutation analysis was
performed in 235 patients with moderate to profound
sensorineural hearing loss. A total of 35.74% deaf pa-
tients showed evidence of genetic involvement based on
either genetic screening or family history, and 17.45%,
9.79%, and 8.51% of the patients were determined to
have inherited hearing impairment caused by GJB2,
SLC26A4, and mtDNA 1555A > G mutations. GJB2 mu-
tation was detected in 16.67% (7/42) of minority patients
and 17.62% (34/193) of Han Chinese patients. SLC26A4
mutation was found in 9.52% (4/42) of minority patients
and 9.84% (19/193) of Han Chinese patients. The fre-
quencies of mtDNA 12S rRNA mutation in minority
and Han Chinese patients were 11.90% (5/42) and
7.77% (15/193). There was no significant difference in
deafness associated gene mutational spectrum or fre-
quency between the Yunnan minority patients and
the Han patients (Table 3). These results will facilitate
effective risk assessment and genetic counseling for
hearing loss patients and their families in Yunnan.
Table 3 Prevalence of GJB2, SLC26A4 and mtDNA 1555A > G mutation in the Asian
Different areas Patients’
number
Prequency of pathologic variants (%) References
GJB2 SLC26A4 mtDNA 1555A > G
Typical areas of China 284 18.31% 13.73% 1.76% Yuan YY et al. [17]
(52/284) (39/284) (5/284)
Yunnan 42 16.67% 9.52% 11.90% This study
(minority) (7/42) (4/42) (5/42)
Yunnan 193 17.62% 9.84% 7.77% This study
(Han Chinese) (34/193) (19/193) (15/193)
Tibet 114 1.75% Yuan YY et al. [40]
(Tibetan) (2/114)
Xinjiang 199 9.05% 2.01% 1.51% Chen Y et al. [41]
(Uyghur) (18/199) (4/199) (3/199)
Korea 1256 1.91% Kim SY et al. [42]
(24/1256)
Japan 1343 14.2% Tsukada K et al. [43]
(1911/1343)
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Sequencing of the GJB2 gene coding region revealed that
14.45% (34/235) of the patients carried two pathogenic
GJB2 mutations and 2.98% (7/235) carried only one
mutant allele. There was no significant difference between
our results and the report of Dai (χ2 = 0.0285, χ2 = 3.6975,
P > 0.05) of 2,063 unrelated NSHI students from 23 re-
gions of China (14.9% had two pathogenic GJB2mutations
and 6.1% carried only one mutant allele) [39].
The 235delC mutation was markedly associated with the
risk of NSHL in East Asian and Southeast Asian popula-
tions, but not significantly in European or Oceanian popu-
lations [28]. In our study, the most common mutation
was c.235delC, followed by c.299delAT. The common
Caucasian mutation c.35delG was not found. Two muta-
tions, c.235delC and c.299delAT, accounted for 80.00%
(60/75) of the GJB2 mutations in our patients, 97% in
a Taiwanese population, and 91% in another Chinese
population.
The 235delC allele frequency in the Yunnan minority
patients (14.29%) was not significantly different from
that in the Han patients (10.36%, χ2 = 1.0790, P > 0.05),
but was higher than that in Tibetan (1.28%,χ2 = 78.2067,
P < 0.05) [40], Uyghur (3.52%, χ2 = 227.6810, P < 0.05)
[41], Korean (0.44%, χ2 = 116.7899, P < 0.05) [42], and
Japanese patients (5.29%, χ2 = 458.1409, P < 0.05) [43].
c.512insAACG and c.9G > A were first reported in
China by Dai. c.512insAACG is a pathogenic alter-
ation with an allele frequency of 0.58% (12/2,063) in the
Chinese population. In our study, three patients carried
c.512insAACG (one homozygote, two compound hetero-
zygotes, and one heterozygote). c.11G >A accounted for
0.43% (1/235) in Yunnan, 10.6% of Taiwanese GJB2 [7,31].c.9G >A, which was a nonsense mutation, carried by one
patient 0.43% (1/235) in Yunnan.
In addition to these mutations, we found a novel
frameshift mutation, c.431_450del 19, in a heterozygous
patient. This mutation was not detected in the control
group. The mutation resulted in a premature stop
codon. It is highly likely to be pathogenic. Regretfully,
we failed to take the history and blood sample from the
family members of the patient, so it is not clear whether
c.431_450del 19 represents an autosomal dominant mu-
tation or is an autosomal recessive with an unidentified
second mutant allele in either the same gene or in a dif-
ferent gene. To clarify the exact roles of the mutation,
careful follow-up and functional studies are needed.
SLC26A4
Mutations in SLC26A4, which encodes Pendrin, are a
common cause of deafness, and responsible for both syn-
dromic and nonsyndromic hearing loss. The SLC26A4
mutation spectrum varies widely among ethnic groups. In
our study population, mutations in SLC26A4 were identi-
fied in 9.79% (23/235) of individuals, which was lower
than that in typical areas of China (18.66%, χ2 = 8.1030,
P < 0.05), but higher than that in Uyghur patients
(2.01%, χ2 = 11.1711, P < 0.05) [41]. In addition, preva-
lent mutations in different ethnic groups are very dif-
ferent. The SLC26A4 mutational spectrum in Yunnan
is similar to that reported in the overall Chinese popula-
tion, with IVS7-2A >G being the hotspot mutation. This
mutation spectrum was different from that in Japanese,
Korean, northern European and Danish populations. In
Japan, H723R is the most prevalent mutation. In Korea,
IVS7-2A >G and H723R are the two most prevalent
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from IVS7-2A >G to H723R from China to Japan, with
Korea in the middle. This observation suggests that IVS7-
2A >G and H723R mutations may be ancient mutations
in China and Japan, respectively. The unique rare muta-
tions evolved more recently. A recent study of 100 unre-
lated patients with EVA in European Caucasians by Albert
et al. revealed a diverse mutation spectrum without preva-
lent mutations; only 40 patients carried SLC26A4 muta-
tions [46]. It is not clear why the mutations in SLC26A4
account for a much lower percentage of patients with
EVA in Caucasian patients. Presumably, other genetic
factors and environmental factors are involved in the
pathogenesis of EVA in Caucasians. A recent study of 109
unrelated probands with EVA in a Danish population re-
vealed that the most frequent mutation was 1246A > C.
This implies that Danish and Chinese populations are of
different ancestry [47].
In our study population, the frequency of SCL26A4
mutation was 9.52% in minority patients, which was not
different from that of Han patients (9.84%; χ2 = 0.0498,
P > 0.05). The allele frequencies of hotspot mutation,
IVS7-2A > G, were 2.38% and 6.64% for minority and
Han populations, respectively. The difference may due
to the relatively small sample size.
It is interesting to note that eight patients with inner
ear malformations carried one pathogenic mutation, and
two patients with inner ear malformations carried no
pathogenic mutation in SLC26A4. If SLC26A4 defects
are the cause of the phenotype of inner ear malforma-
tion, pathogenic mutations may be located in introns or
promoter regions that were not sequenced. Unknown
genes or even environmental factors may contribute to
the malformation.
mtDNA 12S rRNA
MtDNA 12S rRNA A1555G mutation was detected in
nearly 8.51% (20/235) of our nonsyndromic hearing im-
paired population. The mutation in minority patients
was not different from that of Han patients. However,
the mutation rate in Yunnan deaf population was much
higher than that in typical areas of China (1.76%) ac-
cording to Yuan et al. This mutation is found in ap-
proximately 3% of Japanese, 0.5–2.4% of Caucasian
living in Europe or America and 5.3% of Indonesian sen-
sorineural deafness patients [48]. But close to the Guo’
research in northern China (8.56% 44/514) [29]. This is
probably due to two reasons. First, Yunnan is in the
southwest of China, where the overall quality of medical
care is lower than the average in China; aminoglycoside
antibiotic abuse exists. Second, there may be a founder
effect. Northern Chinese are derived largely from the
Mongolian lineage, which is quite different from the an-
cestor(s) of Caucasians in European countries.Our results showed no significant difference in com-
mon deafness genes’ mutational frequencies or spectrum
between the minority patients and the Han patients
from Yunnan Province (χ2 = 0.3189, P > 0.05). However,
the number of individuals included from the non-Han
population may have been too small to draw any conclu-
sions. On the basis of our findings, we recommend that
elective genetic testing be performed in newborns, preg-
nant females, or patients requiring the administration of
aminoglycoside antibiotics to prevent hearing loss in
Yunnan province.
Conclusion
A total of 35.74% deaf patients showed evidence of gen-
etic involvement, based on either genetic screening or
family history, and 17.45%, 9.79%, and 8.51% of these pa-
tients were determined to have inherited hearing impair-
ment caused by GJB2, SLC26A4, and mtDNA 1555A > G
mutations. Our study showed that there was no signifi-
cant difference between Yunnan minority patients and
the Han patients in the deafness-associated gene muta-
tion spectrum. Our study provides much-needed infor-
mation regarding deafness molecular epidemiology of
the Yunnan province, providing a rationale for deafness
gene diagnosis in Yunnan province.
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